<\/p>\n
Surgery is usually the first move against cutaneous squamous cell carcinoma (SCC), the second most common skin cancer. But when a tumor comes with more aggressive features, cutting it out doesn\u2019t always guarantee it stays gone, and until now, doctors have had few tools to lower that risk afterward.<\/p>\n
That may be starting to change. As reported by Dermatology Times<\/em>, a large clinical trial found that giving the immunotherapy drug cemiplimab (Libtayo) for a year after surgery significantly lowered the odds of high-risk SCC returning, compared with a placebo.<\/p>\n<\/div>\n The trial, known as C-POST, gave 415 patients with high-risk cutaneous SCC either cemiplimab or a placebo for a year after their surgery and radiation therapy. Patients on cemiplimab were roughly 70 percent less likely to see their cancer return during the study, a notably strong result for a group already considered high risk for recurrence.<\/p>\n C-POST specifically enrolled patients whose tumors had features linked to a higher chance of coming back or spreading. Dermatologists reviewing the results caution against assuming every SCC patient would see the same benefit. A separate trial testing a different immunotherapy drug in a broader patient group didn\u2019t show the same results, which is a reminder that not every case qualifies. That distinction is worth a real conversation with your own board-certified dermatologist.<\/p>\n For people who\u2019ve faced an aggressive SCC diagnosis, having a treatment to consider after surgery, rather than surgery followed by watching and waiting, is a meaningful shift. It\u2019s still not a decision to make solo. Ask your dermatologist whether your case matches the risk profile that made a difference in this study and keep up with regular self-checks in the meantime. Catching a recurrence early still makes the biggest difference in outcome.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Surgery is usually the first move against cutaneous squ […]<\/p>\n","protected":false},"author":1,"featured_media":2886,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"_links":{"self":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts\/2885"}],"collection":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/comments?post=2885"}],"version-history":[{"count":0,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts\/2885\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/media\/2886"}],"wp:attachment":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/media?parent=2885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/categories?post=2885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/tags?post=2885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What the Trial Found<\/h2>\n
Who This Trial Applies To<\/h2>\n
Where This Leaves Patients<\/h2>\n